PCM
SONM icon

Potomac Capital Management’s DNA X Inc SONM Stock Holding History

Potomac Capital Management’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,000
Closed -$151K – 79
2025
Q4 		$151K Buy
+48,000
New +$431K 0.12% 68

Other funds holding SONM

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CWM
C2C Wealth Management Scottsdale, Arizona $128M AUM 22.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Potomac Capital Management's SONM Position: Q1 2026 in Review

Potomac Capital Management sold out of DNA X Inc (SONM) in Q1 2026, closing a stake of 48,000 shares — an estimated $151K sold.

Potomac Capital Management first reported a position in SONM in Q4 2025 and held it in 1 quarter. The position peaked at $151K in Q4 2025. 9 funds tracked by Wall St. Rank hold SONM as of Q1 2026.

  • Potomac Capital Management reported no remaining DNA X Inc position as of Q1 2026 after selling out during the quarter.
  • Potomac Capital Management sold 48,000 DNA X Inc shares in Q1 2026, an estimated $151K.
  • Potomac Capital Management first reported a position in DNA X Inc in Q4 2025 and held it in 1 quarter.
  • Potomac Capital Management's DNA X Inc position peaked at $151K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held DNA X Inc as of Q1 2026.

Based on Potomac Capital Management's 13F filing for Q1 2026, filed 14 May 2026.